ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding ProPhase Labs, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 29 | 23 | −6 |
| Shares | 1.30M | 1.60M | +308.9K (+23.8%) |
| Value | $9.58M | $9.95M | +$367.0K (+3.8%) |
New holders (3)
Institutions that held ProPhase Labs, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of America Corp | 28,600 | $177.0K | 0.00% |
| State Street Corp | 13,795 | $86.0K | 0.00% |
| Advisory Services Network, LLC | 600 | $4.00K | 0.00% |
Sold out (9)
Institutions that held ProPhase Labs, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Wedge Capital Management L L P | 119,013 | $880.0K |
| FNY Investment Advisers, LLC | 59,400 | $439.0K |
| Marshall Wace, LLP | 50,750 | $375.0K |
| Zeke Capital Advisors, LLC | 35,000 | $259.0K |
| Goldman Sachs Group Inc | 13,373 | $99.0K |
| Trexquant Investment LP | 12,026 | $89.0K |
| Simplex Trading, LLC | 4,497 | $33.0K |
| Barclays PLC | 497 | $4.00K |
| JPMorgan Chase & Co | 2 | $0 |